 | | Vol. 23.00 – 10 January, 2022 |
| |
|
|
| Scientists developed a therapeutic approach to generate transient antifibrotic CAR T cells in vivo by delivering modified mRNA in T cell–targeted lipid nanoparticles.
[Science] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Resarchers developed T cells expressing CARs targeting glypican-2 (GPC2), a fetal antigen expressed on neuroblastoma and several other solid tumors.
[Cancer Cell] |
|
|
|
| Investigators developed a novel class of CAR-T cells engineered to express an enzyme that activated a systemically administered small-molecule prodrug in situ at a tumor site.
[Nature Chemical Biology] |
|
|
|
| Clustered cells from myoblast cell sheets obtained from C57/BL6 mice were administered into ischemic mouse muscles seven days after induction of ischemia.
[Molecular Therapy] |
|
|
|
| In vivo xenograft experiments confirmed D2HGDH-OE CAR-T cell decreased serum D-2-hydroxyglutarate (D2HG) and improved the overall survival of mice bearing NALM6 cancer cells with mutation IDH1.
[Molecular Therapy] |
|
|
|
| Investigators showed that suboptimal T cell receptor stimulation of CD8+ T cells upregulated FOXP3 in vitro.
[Cancer Letters] |
|
|
|
| Scientists assessed the local and systemic innate immune responses to implantation of biphasic calcium phosphate biomaterial alone, or with bone marrow derived mesenchymal stem cells, in critical-sized calvarial bone defects of Lewis rats.
[Acta Biomaterialia] |
|
|
|
| The authors compared second-generation with third-generation carbonic anhydrase IX targeted CAR constructs and investigated the anti-tumor effect of CAR-T cells with different CD4/CD8 proportions in vitro and in vivo.
[Molecular Therapy Oncolytics] |
|
|
|
| The authors assessed the efficacy and safety of B cell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| The authors assessed the efficacy and safety of Bcell maturation antigen (BCMA) and CD38 bispecific CAR-T cells in refractory multiple myeloma patients.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Probing the possible mechanisms of neuroprotection revealed that dental pulp stem cells (DPSCs)/DPSCs-conditioned media treatment upregulated an array of hosts’ endogenous neural survival factors expression.
[Brain Research Bulletin] |
|
|
|
| In a Phase I trial, nine biopsy-proven lupus nephritis patients refractory to standard treatments underwent systemic infusion of 2×106 allogeneic adipose-derived MSCs/kg and were followed for 12 months post-intervention.
[Current Research in Translational Medicine] |
|
|
|
| Researchers examined an expanded cohort of 48 high-risk neuroblastoma patients to identify differences in the late effect profiles for those treated with total body irradiation (TBI) and those treated without TBI.
[Pediatric Blood & Cancer] |
|
|
|
 | | | Investigators address potential future targets to overcome the flaws of CAR-T cell technology in the treatment of cancer, emphasizing glycan antigens, the aberrant forms of which attain high tumour-specific expression, as alternative targets for CAR-T cells.
[Febs Letters] |
| | Scientists present a summary and discussion of the implications of new approaches to improve hematopoietic stem cell transplantation-based therapy.
[Experimental Hematology] |
|
|
|
| The authors reviewvarious articles on tissue engineering in the field of dermatology.
[Tissue and Cell] |
|
|
|
|
| Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.
[Genprex, Inc.] |
|
|
|
| Celularity, Inc. announced the FDA has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, CYNK-001, in development for the treatment of acute myeloid leukemia (AML).
[Celularity, Inc.] |
|
|
|
|
| February 2 – 6, 2022
Salt Lake City, Utah, United States |
|
|
|
|
|
| | Children’s Hospital of Philadelphia – Philadelphia, Pennsylvania, United States |
|
|
|
| | National Institute of Health – Rockville, Maryland, United States |
|
|
|
| | Intima Bioscience – Cambridge, England, United Kingdom |
|
|
|
| | Memorial Sloan Kettering – New York City, New York, United States |
|
|
|
| | Flanders Institute for Biotechnology – Leuven, Belgium |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
